Detrunorm XL 30 mg modified-release capsules

Product Information *

  • Company:

    ADVANZ Pharma
  • Status:

    No Recent Update
  • Active Ingredients :

    *Additional information is available upon request

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 December 2017

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 6.3 - Shelf-life increased from 3 to 4 years$0Section 6.4 - Change from Do not store above 25 ° C to Do not store above 30 ° C. The following has been removed : Bottle: Keep the bottle tightly closed.$0$0$0$0

Updated on 13 December 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 13 December 2017

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 6.3 - Shelf-life increased from 3 to 4 years$0Section 6.4 - Change from Do not store above 25 ° C to Do not store above 30 ° C. The following has been removed : Bottle: Keep the bottle tightly closed.$0$0$0$0

Updated on 13 December 2016

Reasons for updating

  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 10 - change in date of revision of the text

Updated on 13 December 2016

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 10 - change in date of revision of the text

Updated on 13 April 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Free text change information supplied by the pharmaceutical company

update section 4.8 with AE reporting details

Updated on 13 April 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

update section 4.8 with AE reporting details

Updated on 15 June 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2, the quantity of excipient lactose was rounded up from 5.667mg to 5.7mg.

 

In section 4.2 (Posology and method of administration) the word ‘children’ was replaced with ‘paediatric population’. Dose recommendations were added under the heading ‘Patients receiving concomitant treatment with drugs that are potent inhibitors of CYP 3A4 combined with methimazole’.

 

In section 4.3 (Contraindications) the statement ‘women who are pregnant or breast-feeding an infant’ was removed.

 

In section 4.4 (Special warnings and precautions for use) the statement ‘moderate or severe hepatic impairment’ was removed. Also in this section the statement ‘Due to a lack of data Detrunorm XL® 30mg capsules should not be used in children.

 

In section 4.6 (renamed Fertility, pregnancy and lactation) the statement concerning animal studies has been removed. This has been replaced with the statement ‘There are no adequate data from the use of propiverine hydrochloride in pregnant woman. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.’

 

In section 4.7 (Effects on ability to drive and use machinery) the following statement has been added: No studies on the effects on the ability to drive and use machines have been performed.

 

In section 5.2 (Pharmacokinetic properties) the statement ‘This was shown in two placebo-controlled studies with Detrunorm® 15mg Coated Tablets t.i.d over 7 days’ has been added to the paragraph entitled “Patients with glaucoma”.

 

In section 6.5 (Nature and contents of container) the section has been updated to reflect pack sizes manufactured.

 

In section 10 (Date of revision of the text) the date has been updated to July 2011.

Updated on 15 June 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2, the quantity of excipient lactose was rounded up from 5.667mg to 5.7mg.

 

In section 4.2 (Posology and method of administration) the word ‘children’ was replaced with ‘paediatric population’. Dose recommendations were added under the heading ‘Patients receiving concomitant treatment with drugs that are potent inhibitors of CYP 3A4 combined with methimazole’.

 

In section 4.3 (Contraindications) the statement ‘women who are pregnant or breast-feeding an infant’ was removed.

 

In section 4.4 (Special warnings and precautions for use) the statement ‘moderate or severe hepatic impairment’ was removed. Also in this section the statement ‘Due to a lack of data Detrunorm XL® 30mg capsules should not be used in children.

 

In section 4.6 (renamed Fertility, pregnancy and lactation) the statement concerning animal studies has been removed. This has been replaced with the statement ‘There are no adequate data from the use of propiverine hydrochloride in pregnant woman. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.’

 

In section 4.7 (Effects on ability to drive and use machinery) the following statement has been added: No studies on the effects on the ability to drive and use machines have been performed.

 

In section 5.2 (Pharmacokinetic properties) the statement ‘This was shown in two placebo-controlled studies with Detrunorm® 15mg Coated Tablets t.i.d over 7 days’ has been added to the paragraph entitled “Patients with glaucoma”.

 

In section 6.5 (Nature and contents of container) the section has been updated to reflect pack sizes manufactured.

 

In section 10 (Date of revision of the text) the date has been updated to July 2011.

Updated on 20 August 2008

Reasons for updating

  • New SPC for new product

Updated on 20 August 2008

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)